Search

Your search keyword '"Wang, Chang-Li"' showing total 233 results

Search Constraints

Start Over You searched for: Author "Wang, Chang-Li" Remove constraint Author: "Wang, Chang-Li"
233 results on '"Wang, Chang-Li"'

Search Results

1. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

2. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

10. A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

11. METTL3-induced DLGAP1-AS2 promotes non-small cell lung cancer tumorigenesis through m6A/c-Myc-dependent aerobic glycolysis

13. Frankincense Essential Oil Attenuates Dextran Sodium Sulfate-Induced Ulcerative Colitis Through Mapk/Nf-Κb Signaling Modulation

14. Plasma CXCL14 as a Candidate Biomarker for the Diagnosis of Lung Cancer

18. Study on fermentation mechanisms of Arisaema cum Bile based on microbial diversity-odor characteristic components

21. METTL3-induced DLGAP1-AS2 promotes non-small cell lung cancer tumorigenesis through m6A/c-Myc-dependent aerobic glycolysis.

22. Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

27. Urinary malate dehydrogenase 2 is a new biomarker for early detection of non‐small‐cell lung cancer

28. Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer

35. Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer

36. Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma

39. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers

41. Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis

43. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

46. Synthesis of SiC/SiO 2 nanochains by carbonthermal reduction process and its optimization

48. Systematic Identification of CDC34 that Functions to Stabilize EGFR and Promote Lung Carcinogenesis

50. The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro

Catalog

Books, media, physical & digital resources